MedDataX Logo

Effects of Oxytocin on Hemodynamics in Patients Undergoing Laparoscopic Myomectomy

NCT ID: NCT04109339

Last Updated: 2019-09-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-01

Study Completion Date

2020-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project will study the effect of oxytocin on hemodynamics in patients undergoing laparoscopic myomectomy, and how to prevent and manage such hemodynamic changes effectively.It provides a reference for the rational use of oxytocin in clinical practice, which can not only effectively contract the uterus and reduce bleeding, but also reduce the influence on hemodynamics.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oxytocin Hemodynamic Monitoring Laparoscopic Surgery

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Oxytocin Hemodynamic Myomectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group 1 with no oxytocin

Group Type NO_INTERVENTION

No interventions assigned to this group

group 2 with oxytocin 10 U IM + oxytocin 10 U IV

Group Type EXPERIMENTAL

Oxytocin

Intervention Type DRUG

During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.

group 3 with oxytocin 20 U IM + oxytocin 0 U IV

Group Type EXPERIMENTAL

Oxytocin

Intervention Type DRUG

During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.

group 4 with oxytocin 0 U IM + oxytocin 20 U IV

Group Type EXPERIMENTAL

Oxytocin

Intervention Type DRUG

During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxytocin

During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* General anesthesia for gynecological laparoscopic surgery,ASA I\~III

Exclusion Criteria

* Oxytocin use contraindications
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yangzhou University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zhuan Zhang

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

the Affiliated Hospital of Yangzhou University

Yangzhou, Jiangsu, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zhuan Zhang

Role: CONTACT

Phone: +8615062791355

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Zhuan Zhang

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20190501

Identifier Type: -

Identifier Source: org_study_id